Pfizer will expand its China R&D operations by adding facilities in central and western China, according to a Reuters story. The company will build a new clinical R&D center in Wuhan, which will support global clinical drug programs, including Phase I-IV clinical trials. Pfizer did not announce the size of capital commitment to the new R&D center. More details...

Stock Symbol: (NYSE: PFE)